PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : L

Records returned : 109 (on 21 Nov 2024 at 19:49:23).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
02.04.00
Labetalol hydrochloride
Hypertension in pregnancy
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Preferred
Preferred option in pregnancy
02.04.00
Labetalol hydrochloride
Hypertension in pregnancy
Red
Formulations :
  • Intravenous injection (IV)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.04.00
Labetalol hydrochloride
Hypertension (severe / crisis)
Red
Formulations :
  • Intravenous injection (IV)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Hypertensive crisis, post MI and hypertension of pregnancy.
Lacidipine
No Information Returned
04.08.01
Lacosamide
Epilepsy
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Lacosamide
Epilepsy
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
07.02.02
13.02.01
Lactic acid
Bacterial vaginosis
Non Formulary
Formulations :
  • Vaginal gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Lactitol
No Information Returned
01.06.04
Lactulose
Constipation
Green
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
L-Alanyl-l-gutamine
No Information Returned
05.03.01
Lamivudine
HIV infection
Red
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
05.03.01
Lamivudine
Prevention of HIV vertical transmission
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted use - prevention of vertical transmission in babies born to HIV-positive mothers. Use as recommended in BHIVA guidelines
05.03.01
Lamivudine
Hepatitis B
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
RESTRICTED - requires Hepatologist Specialist approval
05.03.01
Lamivudine and zidovudine
HIV infection
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
05.03.01
Lamivudine/raltegravir
HIV infection
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
Lamivudine/tenofovir disoproxil
No Information Returned
Lamivudine/tenofovir disoproxil/doravirine
No Information Returned
04.08.01
Lamotrigine
Epilepsy
Blue
Formulations :
  • Dispersible tablets
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Lanreotide
No Information Returned
01.03.05
Lansoprazole
Acid suppression (Adults)
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
1st line for patients with no swallowing difficulties. 2nd line for adults with swallowing difficulties / feeding tubes - capsules can be opened.
01.03.05
Lansoprazole
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2nd line treatment option in children who are able to swallow capsules. Some capsules are licensed to be opened and have their contents mixed with water, apple/tomato juice or sprinkled on soft food (e.g. yoghurt, apple puree)
01.03.05
Lansoprazole
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2nd line treatment option in children unable to swallow omeprazole or lansoprazole capsules. Oro-dispersible tablets disperse in the mouth to release gastro-resistant granules. Lansoprazole is NOT absorbed sublingually. The gastro-resistant granules must be swallowed for the medicine to be effective. The FasTabs® can also be administered in apple or orange juice.
01.03.05
Lansoprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
1st line in adults with swallowing difficulties. 1st line for patients with enteral feeding tubes.
01.03.05
Lansoprazole
Acid suppression (Adults)
Non Formulary
Formulations :
  • Liquid
  • Oral solution
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Lansoprazole oro-dispersible tablets are 1st-line for adults with swallowing dificulties or enteral feeding tubes.
Lanthanum carbonate
No Information Returned
Lapatinib
No Information Returned
Laronidase
No Information Returned
11.06.00
Latanoprost
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
Latanoprost and timolol
No Information Returned
11.06.00
Latanoprost with timolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
11.06.00
Latanoprost with timolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
05.03.03
Ledipasvir/sofosbuvir
Hepatitis C
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
R
SA
NHSE
NICE
10.01.03
Leflunomide
Respiratory disease indications
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
10.01.03
Leflunomide
Rheumatology indications
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Lenalidomide
No Information Returned
Lenograstim
No Information Returned
Lenvatinib
No Information Returned
Lepirudin
No Information Returned
02.06.02
Lercanidipine hydrochloride
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
05.03.02
Letermovir
Cytomegalovirus
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Letrozole
No Information Returned
06.07.02
08.03.04
Leuprorelin acetate
Transgender Health - Children & Young People
Amber
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
06.07.02
08.03.04
Leuprorelin acetate
Transgender Health - adults
Amber
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
06.07.02
08.03.04
Leuprorelin acetate
Uterine fibroids
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Levamisole hydrochloride
No Information Returned
04.08.01
Levetiracetam
Epilepsy
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Levetiracetam
Epilepsy
Blue
Formulations :
  • Granules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Levetiracetam
Epilepsy
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
11.06.00
Levobunolol hydrochloride
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops (unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care.
Levobupivacaine hydrochloride
No Information Returned
Levocabastine
No Information Returned
Levocarnitine
No Information Returned
03.04.01
Levocetirizine
Allergic rhinitis
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not a 1st-line option. Use cetirizine or loratadine 1st-line.
03.04.01
Levocetirizine
Allergic rhinitis
Non Formulary
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Levodopa
No Information Returned
04.09.01
Levodopa with carbidopa and entacapone
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.09.01
Levodopa with carbidopa and entacapone
Parkinson's disease
N/A
Formulations :
  • Intestinal gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD2
NHSE
Levodopa/carbidopa/entacapone
No Information Returned
05.01.12
11.03.01
Levofloxacin
Bacterial infection
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation.
05.01.12
11.03.01
Levofloxacin
Bacterial eye infection
Blue
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
On specialist recommendation
05.01.12
11.03.01
Levofloxacin
Cystic fibrosis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Nebuliser solution
05.01.12
11.03.01
Levofloxacin
Bacterial infection
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
Levofolinic acid
No Information Returned
04.02.01
04.06.00
Levomepromazine hydrochloride
Nausea and vomiting (chemotherapy induced)
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
6mg or 6.25mg tablets for chemo-related nausea and vomiting. ASPH restricted use - 6mg tablets for paediatric oncology only
04.02.01
04.06.00
Levomepromazine hydrochloride
Nausea and vomiting (chemotherapy induced)
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Levomepromazine maleate
No Information Returned
Levomilnacipran
No Information Returned
07.03.02
07.03.05
Levonorgestrel
Menorrhagia
Green
Formulations :
  • Intrauterine device (progestogen only)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Levothyroxine sodium
No Information Returned
Levothyroxine sodium and liothyronine
No Information Returned
02.03.02
04.07.03
15.02.01
Lidocaine
Post herpetic neuralgia
Green (see narrative)
Formulations :
  • Medicated plaster
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Post herpetic neuralgia only. Acute Trusts are restricted to Pain Team initiation only
02.03.02
04.07.03
15.02.01
Lidocaine
Arrhythmias
Red
Formulations :
  • Infusion
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Lidocaine and tetracaine
No Information Returned
Lidocaine hydrochloride
No Information Returned
Lidocaine/cetylpyridinium
No Information Returned
Lidocaine/prilocaine (Premature Ejaculation)
No Information Returned
Light liquid paraffin
No Information Returned
01.06.07
Linaclotide
Irritable bowel syndrome with constipation (IBS-C)
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
For use after maximal tolerated doses of laxatives from other classes have not helped - review if no response after 4 weeks.
Linagliptin
No Information Returned
Linagliptin/metformin
No Information Returned
05.01.07
Linezolid
Mild to moderate skin and soft tissue infections
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Committee were asked to consider the issues associated with the prescribing of linezolid in primary care for mild to moderate skin/soft tissue infections (SSTIs) in patients: Linezolid prescribing for mild to moderate SSTI in line with HPA recommendations is an option for primary care prescribing especially where referral/admission to secondary care is to be avoided. Primary/secondary care interface: Treatment courses that are initiated in secondary care should be supplied by the Trust in their entirety. GPs should not be asked to prescribe the remainder of linezolid courses. Shared care is therefore not considered appropriate for this drug.
05.01.07
Linezolid
Complicated skin and soft tissue infections
Red
Formulations :
  • Infusion
  • Suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Antimicrobial - requires Microbiology Specialist Approval.
05.01.07
Linezolid
Pneumonia
Red
Formulations :
  • Infusion
  • Suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Antimicrobial - requires Microbiology Specialist Approval.
06.02.01
Liothyronine sodium
Treatment resistant depression
Red
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Un
Important
Consultant psychiatrists only.
Lipegfilgrastim
No Information Returned
Liquefied phenol
No Information Returned
Liquid paraffin
No Information Returned
Liquorice
No Information Returned
06.01.02
Liraglutide
Weight management in adults
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Liraglutide
Weight management in adolescents
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.04.00
Lisdexamfetamine dimesylate
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
02.05.05
Lisinopril
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Use an ARB where possible. If an ACEi is required (patient with heart failure or post MI), ramipril is the preferred option.
02.05.05
Lisinopril
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.05.05
Lisinopril
Hypertension
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Use an ARB where possible. If an ACEi is required (patient with heart failure or post MI), ramipril is the preferred option.
Liquid is very expensive (>£200 for 150ml - Drug Tariff Sep 2024).
Lisinopril with diuretic
No Information Returned
Lisuride maleate
No Information Returned
Lithium carbonate
No Information Returned
Lithium citrate
No Information Returned
Lixisenatide
No Information Returned
11.04.02
Lodoxamide trometamol
Allergic conjunctivitis
Non Formulary
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
Sodium cromoglycate 2% or Antazoline with Xylometazoline (Otrivine-Antistin) are the preferred antihistamine/anti-inflammatory eye drops
Lofepramine hydrochloride
No Information Returned
Lofexidine hydrochloride
No Information Returned
02.12.00
Lomitapide
Homozygous familial hypercholesterolaemia
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
NHSE Specialist Commissioned centres only
Lomustine
No Information Returned
01.04.02
Loperamide hydrochloride
Diarrhoea
Green
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Acute diarrhoea in adults and children over the age of 12 years. Available to purchase from pharmacies.
01.04.02
Loperamide hydrochloride
Diarrhoea
Green (see narrative)
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Reserved for patients with swallowing difficulties. Capsules or tablets are preferred. Available to purchase from a Pharmacy.
01.04.02
Loperamide hydrochloride
Short bowel syndrome
Blue
Formulations :
  • Capsules
  • Oro-dispersible
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Reserve orodispersible tablets (Melts) for patients in whom the tablets or capsules are not suitable. Initiation and first month supply by the specialist before transfer of prescribing to primary care.
Loperamide hydrochloride and simeticone
No Information Returned
05.03.01
Lopinavir and ritonavir
HIV infection
Red
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM specialist approval
Loprazolam mesilate
No Information Returned
03.04.01
Loratadine
Allergic rhinitis
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
03.04.01
Loratadine
Allergic rhinitis
Green
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Loratadine 5mg/5ml oral solution sugar free is the preferred option in patients unable to swallow tablets
04.01.02
04.08.02
Lorazepam
Status epilepticus
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
04.01.02
04.08.02
Lorazepam
Anxiety / anticipatory nausea and vomiting
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
As per St Luke's protocol for the use of anti-emetics with chemotherapy.
Lormetazepam
No Information Returned
Lornoxicam
No Information Returned
02.05.05
Losartan potassium
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Preferred angiotensin II receptor blocker
02.05.05
Losartan potassium
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Losartan potassium with diuretic
No Information Returned
11.04.01
Loteprednol etabonate
Postoperative pain and inflammation (eye)
Red
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Max 14 day treatment - supply from the Trust
Low protein biscuits
No Information Returned
Low protein breads
No Information Returned
Low protein cakes
No Information Returned
Low protein cereals
No Information Returned
Low protein cooking aids
No Information Returned
Low protein desserts
No Information Returned
Low protein grains/flours
No Information Returned
Low protein meals
No Information Returned
Low protein miscellaneous
No Information Returned
Low protein mixes
No Information Returned
Low protein pastas
No Information Returned
Low protein risotto
No Information Returned
Low protein snacks
No Information Returned
Loxapine succinate
No Information Returned
Lubiprostone
No Information Returned
Lumacaftor/ivacaftor
No Information Returned
Lumiracoxib
No Information Returned
Lurasidone
No Information Returned
Lusutrombop
No Information Returned
Lutropin alfa
No Information Returned
05.01.03
Lymecycline
Acne
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation.
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More